Unlike the anti-Covid-19 vaccines developed by Moderna and Pfizer/BioNtech, the vaccine from the American company Novavax (called Nuvaxovid®) does not work on the principle of messenger RNA: it uses the technique of the recombinant Spike S protein of the SARS-CoV-2 coronavirus. Clearly: this vaccine exposes the immune system to a small part of the virus (the Spike protein, therefore) to trigger the production of antibodies.
Authorized in France since February 2022, the Nuvaxovid® vaccine is used according to a vaccination schedule in 2 doses separated by an interval of at least 18 days. In France, as of June 2022, approximately 13,000 French people had been vaccinated with Nuvaxovid® – mainly in Martinique, Guadeloupe, Guyana and La Réunion.
In Europe, 250,000 doses of Novavax have been administered
Yes but here it is: according to the latest opinion of theEuropean Medicines Agency (EMA)published this Thursday, July 14, 2022, the Nuvaxovid® vaccine could cause severe allergic reactions (anaphylaxis).
“People who develop a strong allergic reaction after receiving the first dose of Nuvaxovid® should not receive the second” now indicates the EMA on its site. The vaccine from the company Novavax has been authorized in the United States since mid-July 2022; in Europe, approximately 216,000 doses have been administered since December 2021, and approximately 1,000 adverse effects were recorded.
Read also :
- Covid vaccines: Pfizer, Moderna, Janssen, AstraZeneka, Sanofi
- Medicines, vaccines: how to report side effects?
- Covid-19 vaccination: 62% of chronically ill people are afraid of side effects
